Background Canine obesity is a common disorder accompanied by a low-grade chronic inflammation and is considered a risk factor for liver and heart diseases. The present study aimed to investigate whether an olive oil-derivative enriched in N-acylethanolamines (Olaliamid®, OLA) may protect dogs against obesity-induced comorbidities. Results Twenty-seven dogs of mixed breed and size with a body condition score≥7/9 were included in the trial, once provided they were otherwise healthy. Dogs were fed a commercial maintenance diet for two weeks before enrolment, and randomized in two groups, i.e., OLA (n=14) and placebo (OLA vehicle; n=13). Both treatments were administered orally by the owners in a liquid form at 0.7 ml/5kg body weight, once a day for three months. At baseline and three months later dogs underwent physical examination, blood draw, and echocardiography. At the same timepoints, owners were given a questionnaire about their dog’s general condition. OLA prevented the increase in leptin observed in the placebo group (P=0.011), decreased IL-6 (P=0.043) and derivatives-reactive oxygen metabolites (d-ROMs, P=0.008), and increased biological antioxidant potential (BAP) compared to the placebo group (P=0.032). Moreover, OLA protected the liver, with ALT levels being decreased in the OLA group compared to the placebo one (P=0.005) and bilirubin levels being decreased in the OLA group (P=0.030) but not in the placebo one. OLA showed a cardioprotective effect, with a significant decrease of IVSdN (P=0.028), LVPWdN (P=0.047), IVSd/LVIDd (P=0.015) and LVPWd/LVIDd (P=0.034) compared to the placebo group. According to dog owners, the difficulty rising from lying down significantly increased in the placebo group (P=0.039) but not in the OLA one. Conclusion Overall, OLA improved obesity-induced meta-inflammation and oxidative status and helped to ameliorate liver and heart health as well.

Correction: An olive oil-derived NAE mixture (Olaliamid®) improves liver and cardiovascular health, and decreases meta-inflammation in naturally obese dogs: a double-blind, randomized, placebo-controlled study / Piantedosi, D.; Morelli, G.; Musco, N.; Schievano, C.; Della Valle, M. F.; Pizzo, F.; Nasir, S.; Abate, G.; Ferrara, M.; Lombardi, P.; Cortese, L.. - In: BMC VETERINARY RESEARCH. - ISSN 1746-6148. - 21:article number 694(2025), pp. 1-17. [10.1186/s12917-025-05155-3]

Correction: An olive oil-derived NAE mixture (Olaliamid®) improves liver and cardiovascular health, and decreases meta-inflammation in naturally obese dogs: a double-blind, randomized, placebo-controlled study

Piantedosi D.
Primo
;
Musco N.
;
Pizzo F.;Nasir S.;Abate G.;Ferrara M.;Lombardi P.
Penultimo
;
Cortese L.
2025

Abstract

Background Canine obesity is a common disorder accompanied by a low-grade chronic inflammation and is considered a risk factor for liver and heart diseases. The present study aimed to investigate whether an olive oil-derivative enriched in N-acylethanolamines (Olaliamid®, OLA) may protect dogs against obesity-induced comorbidities. Results Twenty-seven dogs of mixed breed and size with a body condition score≥7/9 were included in the trial, once provided they were otherwise healthy. Dogs were fed a commercial maintenance diet for two weeks before enrolment, and randomized in two groups, i.e., OLA (n=14) and placebo (OLA vehicle; n=13). Both treatments were administered orally by the owners in a liquid form at 0.7 ml/5kg body weight, once a day for three months. At baseline and three months later dogs underwent physical examination, blood draw, and echocardiography. At the same timepoints, owners were given a questionnaire about their dog’s general condition. OLA prevented the increase in leptin observed in the placebo group (P=0.011), decreased IL-6 (P=0.043) and derivatives-reactive oxygen metabolites (d-ROMs, P=0.008), and increased biological antioxidant potential (BAP) compared to the placebo group (P=0.032). Moreover, OLA protected the liver, with ALT levels being decreased in the OLA group compared to the placebo one (P=0.005) and bilirubin levels being decreased in the OLA group (P=0.030) but not in the placebo one. OLA showed a cardioprotective effect, with a significant decrease of IVSdN (P=0.028), LVPWdN (P=0.047), IVSd/LVIDd (P=0.015) and LVPWd/LVIDd (P=0.034) compared to the placebo group. According to dog owners, the difficulty rising from lying down significantly increased in the placebo group (P=0.039) but not in the OLA one. Conclusion Overall, OLA improved obesity-induced meta-inflammation and oxidative status and helped to ameliorate liver and heart health as well.
2025
Correction: An olive oil-derived NAE mixture (Olaliamid®) improves liver and cardiovascular health, and decreases meta-inflammation in naturally obese dogs: a double-blind, randomized, placebo-controlled study / Piantedosi, D.; Morelli, G.; Musco, N.; Schievano, C.; Della Valle, M. F.; Pizzo, F.; Nasir, S.; Abate, G.; Ferrara, M.; Lombardi, P.; Cortese, L.. - In: BMC VETERINARY RESEARCH. - ISSN 1746-6148. - 21:article number 694(2025), pp. 1-17. [10.1186/s12917-025-05155-3]
File in questo prodotto:
File Dimensione Formato  
Piantedosi 2a.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Accesso privato/ristretto
Dimensione 646.73 kB
Formato Adobe PDF
646.73 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1041815
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact